JP2022527556A5 - - Google Patents

Info

Publication number
JP2022527556A5
JP2022527556A5 JP2021559254A JP2021559254A JP2022527556A5 JP 2022527556 A5 JP2022527556 A5 JP 2022527556A5 JP 2021559254 A JP2021559254 A JP 2021559254A JP 2021559254 A JP2021559254 A JP 2021559254A JP 2022527556 A5 JP2022527556 A5 JP 2022527556A5
Authority
JP
Japan
Prior art keywords
methyl
product according
pharmaceutical product
phenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527556A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/026625 external-priority patent/WO2020206289A1/en
Publication of JP2022527556A publication Critical patent/JP2022527556A/ja
Publication of JP2022527556A5 publication Critical patent/JP2022527556A5/ja
Pending legal-status Critical Current

Links

JP2021559254A 2019-04-05 2020-04-03 プロテインアルギニンメチルトランスフェラーゼ5の選択的阻害剤 Pending JP2022527556A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830019P 2019-04-05 2019-04-05
US62/830,019 2019-04-05
PCT/US2020/026625 WO2020206289A1 (en) 2019-04-05 2020-04-03 Selective inhibitors of protein arginine methyltransferase 5

Publications (2)

Publication Number Publication Date
JP2022527556A JP2022527556A (ja) 2022-06-02
JP2022527556A5 true JP2022527556A5 (cg-RX-API-DMAC7.html) 2023-04-07

Family

ID=72666997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559254A Pending JP2022527556A (ja) 2019-04-05 2020-04-03 プロテインアルギニンメチルトランスフェラーゼ5の選択的阻害剤

Country Status (4)

Country Link
US (1) US20220152072A1 (cg-RX-API-DMAC7.html)
EP (1) EP3952874A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022527556A (cg-RX-API-DMAC7.html)
WO (1) WO2020206289A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677B (zh) 2020-07-31 2026-07-28 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
CN117062816A (zh) * 2021-02-04 2023-11-14 美国安进公司 三环-酰胺-双环prmt5抑制剂
US20240262857A1 (en) * 2021-05-27 2024-08-08 Emory University Novel universal anti-rna virus agents
CN113546173B (zh) * 2021-08-19 2022-08-23 徐州医科大学 Prmt5抑制剂在制备治疗冠状病毒感染所引起的疾病的药物中的应用
WO2024012308A1 (zh) * 2022-07-15 2024-01-18 上海和誉生物医药科技有限公司 一种prmt5抑制剂,其制备方法和在药学上的应用
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
EP4553080A1 (en) * 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleoside derivatives as antiviral agents against coronaviruses
US20250313552A1 (en) * 2024-04-04 2025-10-09 New Frontier Bio, Inc. Nicotinate esters and therapeutic methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
HRP20090646T1 (hr) * 2005-03-17 2010-01-31 Proyecto De Biomedicina Cima Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata
WO2009089804A1 (en) * 2008-01-18 2009-07-23 Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. Novel cytostatic 7-deazapurine nucleosides
WO2011075665A2 (en) * 2009-12-18 2011-06-23 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016079321A1 (en) * 2014-11-20 2016-05-26 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of setdb2 for use in the therapy of infectious diseases
TWI730980B (zh) * 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
LT3399984T (lt) * 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
CN110325188A (zh) * 2016-10-26 2019-10-11 印第安纳大学理事会 小分子蛋白质精氨酸甲基转移酶5(prmt5)抑制剂和治疗方法
MA49840A (fr) * 2017-08-09 2020-06-17 Prelude Therapeutics Inc Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2020033285A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) * 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Similar Documents

Publication Publication Date Title
ES2521672T3 (es) Formulaciones farmacéuticas para el tratamiento del cáncer
JP2020512337A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2019515884A5 (cg-RX-API-DMAC7.html)
JP2007246536A (ja) 1−(2−(ヒドロキシメチル)−1,3−オキサチオラン−5−イル)−5−フルオロシトシンのb型肝炎治療への使用
JP2005527605A5 (cg-RX-API-DMAC7.html)
JP2021534099A5 (cg-RX-API-DMAC7.html)
JP2007520452A5 (cg-RX-API-DMAC7.html)
JP2010500962A5 (cg-RX-API-DMAC7.html)
WO2021248022A1 (en) Methods of treating a coronavirus infection
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2023546565A5 (cg-RX-API-DMAC7.html)
CA2555457A1 (en) A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
JP2006516643A5 (cg-RX-API-DMAC7.html)
JP2020511437A5 (cg-RX-API-DMAC7.html)
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
JP2022534776A5 (cg-RX-API-DMAC7.html)
RU2008138749A (ru) Производные камптотецина и их применение
JP2008509210A5 (cg-RX-API-DMAC7.html)
JP2024520567A (ja) 肺線維症の予防または治療用の薬学製剤
JP2021503448A5 (cg-RX-API-DMAC7.html)
WO1995007282A1 (en) Depression remedy
JP2011111418A (ja) 口腔内局所投与に適したウイルス感染予防製剤
JPH06506929A (ja) B型肝炎ウイルス感染の治療のための、1,3−オキサチオラン誘導体の使用
RU2294198C2 (ru) Производные арил(или гетероарил)азолилкарбинола для лечения респираторных заболеваний